Article scientifique	Méta-analyse	2011

Published version	Open Access

- -

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

- -

Ferrari-Lacraz, Sylvie; Ferrari, Serge Livio

How to cite

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

S. Ferrari-Lacraz · S. Ferrari

Abstract Receptor activator of nuclear factor kappa B ligand (RANKL) and its natural antagonist, osteoprotegerin (OPG), are, respectively, an indispensable factor and a potent inhibitor for osteoclast differentiation, activity, and survival. The development of a human monoclonal antibody to RANKL, denosumab, constitutes a novel approach to prevent fragility fractures in osteoporosis, skeletal complications of malignancy, and potentially bone erosions in rheumatoid arthritis (RA). In addition to being expressed by osteoblasts, RANKL is abundantly produced by activated T cells, and synoviocytes in RA, whereas its receptor, RANK, is also expressed by monocytes/macrophages and dendritic cells. However, in preclinical and clinical studies of RA—including patients with some degree of immunosuppression—RANKL inhibitors did not significantly alter inflammatory processes. RANKL, RANK, and OPG deficiency in murine models highlights the important role of this pathway in the development and maturation of the immune system in rodents, including functions of T and/or B cells, whereas OPG overexpression in mice and rats seems innocuous with regard to immunity. In contrast, loss-of-function mutations in humans have more limited effects on immune cells. In clinical studies, the overall rate of infections, cancer, and death was similar with denosumab and placebo. Nevertheless, the risk of severe infections and cancer in some specific tissues remains to be carefully scrutinized.

Keywords Denosumab · Immunity · Inflammation · OPG · Osteoporosis · RANKL

S. Ferrari-Lacraz
Transplantation Immunology Unit, Division of Immunology and Allergy and Division of Laboratory Medicine, Department of Medical and Genetic Laboratories, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

S. Ferrari
Division of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland

S. Ferrari (✉)
Service des Maladies Osseuses, Geneva University Hospital (HUG), 6, rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland
e-mail: Serge.Ferrari@unige.ch

Introduction

Local and systemic bone loss (osteoporosis) that occurs in inflammatory diseases and gonadal steroid deficiency, subchondral bone erosion in rheumatoid arthritis (RA), as well as osteolytic bone metastasis, are all caused by the bone-resorbing effects of osteoclasts. Two factors secreted primarily by bone marrow stromal cells and osteoblasts are necessary and sufficient to induce differentiation of hematopoietic precursors common to the monocyte/macrophage and osteoclast lineages into multinucleated, bone-resorbing cells: colony-stimulating factor-1 (CSF-1 or M-CSF) and the tumor necrosis factor (TNF)-related cytokine receptor activator of nuclear factor kappa B ligand (RANKL) [1, 2]. By engaging specific adaptor molecules, such as the TNF receptor-associated factor TRAF6 and the Grb-2-associated binder-2 Gab2, RANKL binding to its receptor RANK further promotes activation and survival of mature osteoclasts [3–5]. In both mice and humans, deleting or inactivating mutations of RANKL and RANK genes results in the absence of osteoclasts and osteopetrosis [6–9].

Osteoblasts/stromal cells also produce osteoprotegerin (OPG), a decoy receptor which binds RANKL, thus preventing its own binding to RANK. Thereby, OPG exerts a negative regulation on osteoclastogenesis, promotes apoptosis of mature osteoclasts, and ultimately inhibits bone resorption [10]. Hence, OPG-deficient mice exhibit increased bone turnover, a reduction in cortical and trabecular bone volume, and they develop spontaneous fractures [11]. In contrast, overexpression of OPG or RANK-Fc (that functions as a RANKL inhibitor) in transgenic rodents causes high bone mass, but without the typical features of osteopetrosis, as in these models, bone mass correlates with the level of OPG or RANK-Fc expression [10, 12, 13]. Hence, the discovery of the RANKL/RANK/OPG pathway has led first to the development of recombinant OPG (rhOPG) and OPG-Fc, then to that of a fully human IgG2 monoclonal antibody to RANKL named denosumab, as a novel therapeutic agent for potential application in osteoporosis [14, 15], RA [16], and cancer [17].

Besides being produced by osteoblasts, RANKL is also abundantly expressed by activated CD4$^+$ T cells, whereas mature B cells express OPG [18, 19]. Many cytokines produced by monocytes and/or T cells have actually been identified as stimulators of bone resorption, including interleukin (IL)-1, IL-4, IL-6, IL-7, IL-15, IL-17, interferon (IFN)-γ, and TNF-α [20–28]. Hence, T lymphocytes are key to the process of local and systemic bone loss associated with inflammation, autoimmune diseases, and graft rejection [29, 30] and also play a role in bone loss due to estrogen deprivation [31]. The point is that RANKL-producing T cells not only contribute to osteoclast activation [18, 19] but also to the co-stimulation of other RANK-expressing cells, such as dendritic cells (DC) and monocytes/macrophages [32, 33] (Fig. 1).

In addition to inhibiting osteoclastogenesis, RANKL inhibitors could therefore potentially modulate and/or inhibit an array of T-cell-mediated reactions, which has raised some concerns about their specificity and safety. This review focuses on the experimental evidence as to the role of the RANKL/RANK pathway and its inhibitors on inflammation and immunity.

Effects of RANKL inhibitors on inflammatory diseases

Comparing and contrasting the effects of RANKL and TNF inhibitors

Administration of agents blocking TNF-α or IL-6 in both animal disease models and humans has proven efficient in controlling inflammatory processes characteristic of RA [34–37] and other autoimmune diseases [38, 39]. Treatment of RA with TNF-specific antagonists, such as etanercept, infliximab, and adalimumab, also prevents subchondral erosions and cartilage destruction [35, 40–42], whereas their effects on the preservation of systemic bone mass seem limited when withdrawal of corticosteroids is taken into consideration [41, 43, 44]. Treatment of patients suffering from RA or other inflammatory disorders by biological agents that target members of the TNF family has shown an increase in the number of infections and hematologic malignancies (Table 1) [45–47]. Admittedly, TNF inhibitors significantly increase the risk of contracting tuberculosis and of its reactivation [45, 48]. Several investigators demonstrated that transmembrane TNF-α (TmTNF) plays an important role in the inflammatory response to infection, as TmTNF contributes to the induction and regulation of Th1-type cytokines and chemokine expression which is crucial for the development of bactericidal granulomas and resistance to mycobacterium infections [49, 50]. Moreover, TNF-α also appears to fulfill an important regulatory function in controlling repair and regenerative processes after tissue damage [51].

Similar to TNF, RANKL is abundantly produced by infiltrating T cells and synoviocytes in RA [7, 52–54]. In contrast to TNF inhibitors, however, OPG administration in animal models of RA, such as the rat model of adjuvant-induced arthritis and TNF-α transgenic (Tg) mice—which spontaneously develop arthritis—did not alter the severity of joint inflammation, despite a marked reduction of periarticular bone erosions, as well as of cortical and trabecular bone loss at distant skeletal sites [7, 55]. Even RANKL$^{-/-}$ mice remained susceptible to arthritis induced by serum transfer [55]. Recently, Stolina et al. compared the effects of the RANKL inhibitor OPG-Fc, the TNF-α inhibitor pegsunercept, and the IL-1 inhibitor anakinra on rats with established adjuvant- or collagen-induced arthritis [56]. Parameters of local and systemic inflammation (paw swelling and serum levels of pro-inflammatory cytokines) were dramatically decreased by anti-TNF-α or anti-IL-1 therapy, while local, but not systemic, bone loss was partially reduced. In contrast, OPG-Fc therapy inhibited local and systemic bone loss in both arthritis models without modifying local or systemic inflammation.

In a phase II clinical trial, administration of 60 or 180 mg s.c. of denosumab every 6 months to patients with active RA (and receiving methotrexate) halted the progression of subchondral bone erosions and systemic bone loss, although without an apparent reduction of clinical inflammation and joint space narrowing [7, 16, 55, 57]. Altogether, these observations suggest that—contrary to anti-TNFs—RANKL and its inhibitors do not play a major part in T-cell-mediated inflammatory processes in RA, which could be accounted for by the redundant effects of an array of pro-inflammatory cytokines [58]. Moreover, in the

Fig. 1 RANKL-mediated crosstalk between immune cells and osteoclasts. RANK ligand is an essential mediator of osteoclast formation, function, and survival and is produced not only by bone marrow stromal cells and osteoblasts but also by T cells. RANKL binds to the RANK receptor, which is expressed by monocytes/ macrophages (Mo/Mø) and osteoclast precursors, dendritic cells (DCs)/antigen-presenting cells (APC), and T cells. The RANKL antagonist and TRAIL-binding factor OPG is expressed by mature osteoblasts and B cells (as well as by other cell types not shown here) and inhibit RANKL-induced osteoclastogenesis

above clinical trial, the rate of adverse events and serious infections requiring hospitalization did not differ between patients treated with denosumab and those with placebo, although the episodes of influenza (self-reported), upper respiratory tract, and urinary tract infections were numerically higher in the denosumab group. Hence, in a recent survey, rheumatology experts raised some concerns that the risk of infection with RANKL inhibitors could be worsened if employed concomitantly to anti-TNFs and/or other biological agents [59].

Inflammatory bowel diseases

In the $CD4^+$ $CD45RB^{Hi}$ T-cell transfer mouse model of inflammatory bowel disease (IBD), the effects of OPG-Fc administration were similar to those in RA: While dramatically improving bone density, OPG-Fc did not modify inflammatory parameters nor reduce infiltration of the gastrointestinal tract by inflammatory cells (colitis) [60]. In contrast, in IL-2-deficient mice—that spontaneously develop an autoimmune disease characterized by hyperactivation of $CD4^+$ T cells with multi-organ inflammation and massive T-cell infiltration of the gastrointestinal tract— administration of OPG-Fc not only led to a significant

increase in bone density but also improved gastrointestinal tissue architecture [61]. In this particular model, by antagonizing RANKL expressed by T cells, it is possible that OPG-Fc interrupted the amplification loop of T-cell activation and infiltration in colonic tissues mediated by DCs (Fig. 2). Hence, in models where major immunologically active molecules are deleted (e.g., IL-2 KO and CD40 KO [62]), RANK/RANKL signaling may become the main co-stimulatory pathway for crosstalk between T and B cells and DCs [32, 62, 63].

Whether these models are of clinical relevance however remains uncertain, and it is therefore hardly surprising that in most circumstances, RANKL inhibitors did not alter tissular inflammation.

Effects of RANKL/RANK/OPG on T- and B-cell-mediated immunity

Effects on the immune system organogenesis and T cells

While innate immune responses induced by inflammation represent a physiological (and sometimes pathophysiological), non-specific reaction to pathogens (and self-antigens)

Table 1 Properties of anti-tumor necrosis factor and anti-RANKL antibodies in humans

Description	Anti-TNF	Anti-RANKL
Drug structure	Soluble TNFRII-human Fc fusion protein (etanercept)	Human monoclonal IgG2 antibody (denosumab)
Potential indications	Rheumatoid arthritis	Osteoporosis
	Juvenile chronic arthritis	Skeletal complications of malignancy
	Psoriatic arthritis	
	Ankylosing spondylitis	Rheumatoid arthritis
	Psoriasis	
Effect on T cells	Induces apoptosis	NA
	Increases Treg	
Effect on B cells	No direct effect	NA
Effect on mono-mφ	Induces apoptosis	NA
	Decreases production of inflammatory cytokines	
Adverse events		
Infectious	Tuberculosis	Cellulitis/erysipelas[a]
	Bacterial infections	Diverticulitis[a]
	Intracellular pathogens	
	Upper respiratory tract	
Tumoral	Lymphoma, mostly non-Hodgkin's	Breast?[b]
		Reproductive (ovary)?[b]
		Gastrointestinal?[b]
Others		Dermatitis and Eczema[c]
		Hypersensitivity?
Auto-antibodies	Very frequent: ANA, anti-dsDNA, anti-cardiolipin, but their formation is not associated with specific clinical syndrome	None

Concerning RANKL antagonist effects on immune cells in animals and in vitro, see text

NA data not available in humans

[a] In the post-menopausal osteoporosis and HALT trials combined

[b] In the post-menopausal osteoporosis trials only. The "?" indicates that the significance of these observations is still unclear (according to the FDA advisory committee for reproductive health drugs, August 2009)

[c] In the post-menopausal osteoporosis trials

and lack memory, the adaptive immune response is characterized by a high degree of specificity and memory, involving specialized and highly differentiated cells. A prerequisite of specific innate and adaptive immune responses is the stepwise maturation of T and B lymphocytes, and there are distinct stages in the development of lymph node (LN) organogenesis that require the specific expression of adhesion molecules, cytokines, and chemokines. LN, Peyer's patches, and nasal-associated lymphoid tissue (NALT) seem to follow a common developmental program, whereas spleen organogenesis undergoes an even more complex process.

Studies in mice have mapped numerous genes essential for lymphoid tissue development [64], including members of the TNF family such as surface lymphotoxin LTα1β2 and RANKL. LTα1β2 signals through the lymphotoxin β receptor (LTβR), and mice deficient in LTα, LTβ, or LTβR lack LN [65–67]. Similarly, in the absence of RANKL,

RANK, or TRAF-6, LN cannot develop, whereas the formation of Peyer's patches, NALT, and splenic microarchitecture is not affected [6, 18, 68, 69]. In RANKL-deficient mice, impaired LN development results from a defect in colonization and cluster formation of hematolymphoid precursor cells [68], particularly α4β7+ CD4+ CD3− T cells. Thymus size and cellularity of these mice are diminished, indicating that RANKL further contributes to early thymocyte development [18]. Although the total number of T lymphocytes as well as their production of IFN-γ and IL-2 is lower in RANKL−/− mice, they do proliferate adequately, and the subsets of CD4+ and CD8+ T cells occur in normal amounts, probably owing to redundant co-stimulatory pathways (such as CD40-CD40L and CD28-CD80/86), indicating that thymus function remains unaffected. Intriguingly, RANK−/− mice boast normal thymic development, a normal percentage of thymocytes and T-cell precursors [6]. Consequently, as suggested by

Fig. 2 Role of RANKL/RANK signaling on co-stimulation of innate immune cells. Interaction between T lymphocytes and DC as well as their activation occur (1) through the T-cell receptor (TCR)-HLA complex and (2) through co-stimulatory complexes such as CD28/B7 or CD40L/CD40 molecules. RANKL interaction with RANK promotes DC survival [62] and enhances monocyte functions [33]. This interaction is similar to that of the co-stimulatory CD40L/CD40 interaction [98]. CD40L is rapidly expressed by activated T cells, whereas RANKL expression occurs within 48 h. Consequently, CD40L/CD40 interaction is key to controlling the priming stage, whereas RANKL/RANK interaction may take place later and is of a more accessory nature [99]

these authors, RANKL signaling in the thymus might also be mediated through a receptor other than RANK [6].

Contrasting with RANKL- and RANK-deficient mice, highly expressing OPG-transgenic (OPG-Tg) mice present no alterations of LN, thymus, or spleen [70]. OPG-Tg rats present normal LN development at gestational day 11 when OPG levels are already high [70], suggesting that even residual effects of RANKL may be sufficient in this regard. Similarly, the administration of RANKL-Fc in mice did not affect cytokine production and proliferation of T cells, nor did it modify T-lymphocyte infiltration of inflammatory tissues [71]. Moreover, when OPG or RANKL are added to wild-type murine T-cell cultures, their proliferation and production of cytokines remain unaffected, suggesting that RANKL signaling is not crucial for mature T-cell functions [18].

Finally, patients with mutations in the *TNFSF11* (*RANKL*) gene or in the *TNFRSF11A* (*RANK*) gene have normal lymphocyte counts of the peripheral blood and do not present major abnormalities in T-cell phenotypic and functional properties [8, 9].

Effects on B cells

RANKL$^{-/-}$ mice exhibit a marked alteration of B-cell development with defective transition of pro-B to pre-B and reduced numbers of B cells in the spleen [18]. In RANK$^{-/-}$ mice, the developmental defect in the B-cell lineage is massive with a decrease in mature B cells in the bone marrow and peripherally [6]. In three out of the eight patients with osteoclast-poor osteopetrosis due to mutations

in the *TNFRSF11A* (*RANK*) gene, the number of mature B cells was significantly decreased, and their serum immunoglobulin levels (particularly IgG) were low. Moreover, two of these patients failed to produce antibodies to tetanus toxoid vaccination [9]. Of note, their Ig level—although reduced—was not as low as that observed in patients with common variable immune deficiency. Furthermore, the reasons for the hypogammaglobulinemia in patients with mutations in the *TNFRSF11A* (*RANK*) gene may be as follows: (1) in response to RANKL, osteoclasts are unable to produce high levels of APRIL, a player of B-cell activation and isotype switching, and (2) the marked osteopetrosis limits anatomic niches for B-cell development and survival in bone marrow [72]. In addition, patients with osteoclast-poor osteopetrosis due to mutations in the *TNFSF11* (*RANKL*) gene affecting its cell surface presentation were not reported to suffer from immunological deficiencies nor to be particularly prone to infection [8]. To explain the discordant observations concerning B-cell functions in these patients with RANKL and RANK mutations, it has been hypothesized that the mutant RANKL protein might still retain some selective activity on immune cells [8] which, to our knowledge, has not yet been substantiated.

In OPG$^{-/-}$ mice, proliferation of pro-B cells is increased, but there is a deficit in antibody response to antigen due to an alteration in the isotype switch of IgGs, suggesting that OPG is essential for B-cell maturation and development through its inhibitory effect on TRAIL [73, 74]. In contrast, OPG-Tg mice and rats present neither a defect in B-cell development and maturation nor impaired humoral response to immune challenges [70], confirming that these rodents are immunocompetent. In addition, in mice treated with OPG-Fc and injected with a pneumovax vaccine, production of IgM and IgG subtypes was identical to that of mice injected with control-Fc (Table 2) [75]. Moreover, administration of denosumab to adult ovariectomized cynomolgus monkeys over a period of 15 months had no apparent effect on basal immune parameters and did not elicit any effect on T, B, or NK cells at any time point [76].

In summary, mouse genetic models clearly indicate that the RANKL/RANK/OPG pathway is essential to the development of lymphoid organs and T and B cells, whereas experiments of nature in humans show that loss-of-function mutations in this system have only moderate and selective effects on B-cell immunity. On another side, overexpression of OPG even from the embryonic stage, as well as administration of RANKL antagonists, do not appear to impair the development and/or activation of T and B cells (Table 3). These results also suggest that RANKL inhibitors do not impair autoimmunity, since autoimmune diseases and some allergic diseases are partly due to a defect in IgG switching [77, 78].

Table 2 Comparative phenotypes of RANK$^{-/-}$, RANKL$^{-/-}$, and OPG$^{-/-}$ mice

	RANK$^{-/-}$ mice	RANKL$^{-/-}$ mice	OPG$^{-/-}$ mice
Bone	Osteopetrotic; no osteoclast present	Osteopetrotic; no osteoclast present	Osteoporotic; osteoclast activation
Thymus	Normal size; thymocyte dvp normal	Reduced size; thymocyte dvp impaired	Normal size
LN	LN agenesis; Peyer's patches smaller	LN agenesis; Peyer's patches smaller	Normal LN dvp; Peyer's patches normal
Spleen	Normal; extramedullary hematopoiesis	Normal; extramedullary hematopoiesis	Normal
L$_T$	Normal T-cell dvp; CD4/CD8 ratio N	Deficit in early intrathymic T-cell dvp CD4/CD8 ratio N	Normal T-cell dvp; CD4/CD8 ratio N
L$_B$	B-cell dvp ND; reduced number of B-cells	B-cell dvp impaired; reduced number of B-cells	Increased number of B-cells; altered Ig isotype switching
DC	Normal dvp and function/activation	Normal dvp and function/activation	Increased survival and function/activation

Adapted from Dougall et al. [6]

LN lymph nodes, *dvp* development, *L$_B$* lymphocytes B, *L$_T$* lymphocytes T; *Ig* immunoglobulin, *DC* dendritic cells, *ND* not determined

Effects of RANKL/RANK/OPG on other immune cells

Immune cells need to interact with each other in order to initiate an innate and adaptive immune response and to produce pro- and anti-inflammatory cytokines, chemokines, and antibodies to pathogens. DCs and monocyte/macrophages are key components of the innate immune response and are major antigen-presenting cells (APC) priming T cells to proliferate and initiate an adaptive immune response [79]. In turn, activation and proliferation of T cells control antigen dispersion and, due to the secretion of cytokines, trigger a feedback amplification loop that further enhances functions of DC and monocyte/macrophages, as well as B-cell proliferation and antibody production in order to control the dissemination of antigens.

Effects on monocyte–macrophages

Monocyte–macrophages are closely related to osteoclasts and express RANK on their cell surface. Monocytes from peripheral blood as well as monocytic cell lines both differentiate into osteoclasts when cultured with M-CSF and RANKL [1]. Stimulation of monocytes with RANKL induces the expression of Bcl-xl, pro-inflammatory cytokines such as IL-1β and TNF-α, chemokines, co-stimulatory molecules (CD80 and CD86), and MHC-II on

Table 3 Evaluation of RANKL inhibition on immune parameters in preclinical models

		Length of RANKL inhibition		
		Short-term (<3 weeks, OPG- or RANK-Fc)	Long-term (>1 year, dmab)	Life-long (OPG-Tg)
Baseline immune profile	Cellular composition of blood [70]		Cyno	Mouse, rat
	Systemic cytokine levels [70]			Mouse, rat
	Systemic immunoglobulin levels [70, 75]	Mouse		Mouse, rat
	T and B cell proliferation in vitro to specific antigens [70, 75]	Mouse		Mouse, rat
Immune challenge	Delayed contact hypersensitivity to oxazolone in skin [70, 75]	Mouse		Mouse
	Innate response to LPS [70]			Mouse, rat
	T-cell-dependent immune response to KLH [70, 75]	Mouse	Cyno	Mouse
	T-cell-independent immune response to Pneumovax [70, 75]	Muse		Mouse
Infectious disease	BCG bacterial infection [70]	Mouse		
	Influenza viral infection [97]	Mouse		
Autoimmune disease	Immune-mediated arthritis [56]	Rat		
	Inflammatory bowel disease [60]	Mouse		

their cell surfaces, which protects these cells from apoptosis, increases their phagocytic properties, and activates antigen presentation [33]. However, in studies on RANKL$^{-/-}$ mice, both the number and distribution of monocyte–macrophages were normal [18]. Differentiation and function of monocyte–macrophages were also preserved in RANK$^{-/-}$ mice, demonstrating that contrary to osteoclastogenesis, the RANKL/RANK pathway is not crucial to macrophage development [6]. However, the role of RANKL/RANK in monocyte–macrophage functions becomes more prominent when other essential co-stimulatory molecules are missing, such as in mice lacking CD40L [80], a T-cell surface protein that is essential for activation of monocyte–macrophages and a close relative to RANKL [32, 81]. Whether RANKL antagonists would similarly worsen the deficient monocyte–macrophage functions in patients with the hyper-immunoglobulin M syndrome due to CD40 mutation or with CD40L deficiency is currently unknown.

Most important in terms of the pharmacological effects of denosumab on both immunity and control of infection, blockade of RANKL function in vivo by RANK-Fc did not alter the functions of monocytes, nor did it amplify inflammatory processes in mice models of lipopolysaccharide (LPS)–endotoxic shock and inflammatory arthritis [33]. LPS is a component of cell walls of Gram-negative bacteria and a potent activator of monocyte/macrophage function due to its interaction with CD14 and toll-like receptor 4 (TLR4). LPS activation of monocyte/macrophages also induces co-stimulatory proteins such as CD40, CD80, and CD86, which in turn activate T cells. Therefore, even if the RANKL/RANK pathway is inhibited, redundancy of activating pathways and immune cell interactions will sustain the immune response to pathogens. As further proof of this concept, OPG administration to mice infected with *Mycobacterium bovis* did not alter their immune response [75].

Effects on antigen-presenting cells (APC)

APC play an essential role in the presentation of foreign peptides or altered self-peptides to T lymphocytes and thus in the induction of antigen-specific T-cell activation. APC are mainly composed of DCs and Langerhans cells (LC), a subset of DCs found in the skin epithelium and in mucosae. T cells that express RANKL play an agonistic role on DC activation in vitro due to co-stimulatory processes involving CD40L/CD40 interaction (see above) [32]. Hence, RANKL enhances DC survival, antigen presentation [62, 63], and production of cytokines [82]. Accordingly, in OPG$^{-/-}$ mice, due to the increased survival of DCs, the DC–T-cell interaction may be prolonged and T-cell proliferation more pronounced [73]. However, in RANKL$^{-/-}$ mice and

RANK$^{-/-}$ mice, DC development and function are intact, with normal expression of DC surface markers and co-stimulatory markers, and the appropriate stimulation of alloreactive T cells [6, 18]. Phenotypic and functional analyses of DCs in subjects with either *TNFSF11* (*RANKL*) or *TNFRSF11A* (*RANK*) gene mutations also did not reveal any major abnormalities [8, 9]. Thus, although RANKL appears to be an effective co-stimulatory factor, it is not essential for DC activation.

Like DCs, LCs also express RANK, and LC proliferation and survival is impaired in RANKL$^{-/-}$ mice [83, 84]. Ultraviolet exposure or inflammation upregulated the expression of RANKL by inflamed keratinocytes leading to an increase of regulatory CD4$^+$ CD25$^+$ T cells [83], which in turn helps to control cutaneous inflammation and hyperallergic responses. Loser et al. [83] demonstrated that in transgenic mice expressing RANKL under the transcriptional control of the keratin-14 (K14) promoter (K14-RANKL Tg mice), the number of regulatory CD4$^+$ CD25$^+$ T cells was increased by activation of DCs, and contact hypersensitivity responses were decreased.

Effects of RANKL inhibition on immune surveillance of cancer

Both innate and adaptive immune mechanisms are implicated in the surveillance of cancer. Thus, antigen-presenting DCs, CD8 cytotoxic T lymphocytes, and CD4 T helper cells and, more specifically, natural killer (NK), regulatory T cells (Treg), and T$\gamma\delta$ cells interact in controlling and eventually eliminating tumor cells. A large number of cytokines and chemokines have been implicated in the immune response to cancer, since they amplify the inflammatory reaction—as in the case of IL-2—and/or cause lysis (by apoptosis) of tumor cells—as in the case of IFN-γ. It follows that although it is not essential, the immunomodulatory effect of RANK signaling on the various effectors of this system described above could affect immune surveillance of cancer. CD4$^+$ T cells in particular can generate direct cytotoxicity via TRAIL. When added together with TRAIL to osteoblast-like cell cultures, OPG prevents TRAIL-induced apoptosis [85]. OPG secreted by prostate cancer cells may also protect them from TRAIL-induced apoptosis [86]. Therefore, the binding of OPG to TRAIL and interference with the natural defense mechanism against tumorigenesis is a potential concern related to OPG treatment. In this regard, denosumab has the advantage over OPG in that it does not bind to TRAIL [87]. On the other hand, inhibiting the excess RANKL commonly produced in bone infiltrated by tumor cells interrupts the

vicious circle of bone lysis stimulation of metastatic growth, which can prevent the skeletal progression of cancer, at least in preclinical models [88].

Risk of infection and cancer associated with denosumab in clinical trials

In a combined cohort of more than 8,000 post-menopausal women with osteoporosis from fracture (FREEDOM) and bone loss prevention [89, 90], the incidence of serious adverse events was similar in the denosumab and placebo (PBO) groups (25.3% and 24.3%, respectively), but denosumab tended to decrease the risk of death (HR, 0.76; CI, 0.55–1.03; $p=0.08$). In a combined cohort of about 1,700 subjects with non-metastatic breast cancer, i.e., including patients who faced a higher risk of infections and death, the incidence of serious adverse events and death was also similar in denosumab and PBO groups (31.6% vs 27.6% and 5.2% vs 5.6%, respectively) [91, 92]. Combining the results of these four studies (~10,000 subjects), infections were reported in 50.6% of subjects in the PBO group and 50.1% in the denosumab group, while serious infections were found in 4.3% and 3.4% of subjects treated with denosumab and PBO, respectively (NS). Sepsis (≤0.2%) and opportunistic infections (≤2%) including tuberculosis and fungal infections were rare, and their incidence was similar in the two groups. Severe pneumonia (1%), bronchitis (0.2%), and urinary tract infections (0.3%) also occurred in similar proportions in the two groups, while rare cases of severe skin infections (mostly at lower extremities) and diverticulitis were observed more frequently with denosumab than with PBO (erysipelas/cellulitis, 0.2% PBO, 0.4% denosumab; diverticulitis, 0.1% PBO, 0.3% denosumab). Considering the role of RANKL/RANK in the modulation of the immune/inflammatory responses in the skin (see above) and the small but significantly higher number of patients with eczema among post-menopausal women treated with denosumab as compared to placebo (FREEDOM), we suggest that RANKL inhibitors could amplify cutaneous allergic and inflammatory responses rather than increase susceptibility to infection itself. A recent meta-analysis including the FREEDOM trial and using a model of fixed rather than random effects revealed a significantly higher risk of serious infections in women with osteoporosis or osteopenia treated with denosumab than in controls (RR=1.26, CI=1.01–1.57, $p=0.04$). When patients with non-metastatic breast cancer (HALT trial) were excluded, the risk increase was of borderline significance (RR=1.25, CI=1.00–1.59; $p=0.05$).

The overall incidence of cancer in post-menopausal women from the FREEDOM trial and the bone loss prevention trial did not differ between denosumab (4.8%)

and placebo (4.2%), nor did the number of malignancy-related deaths in both the FREEDOM and HALT prostate cancer [91] trials together (denosumab $n=26$, PBO $n=35$). In the combined sample of 8,091 post-menopausal women, there were no differences between denosumab and PBO in the number of skin, lung/mediastinum, or hematopoietic neoplasms including lymphomas, whereas the denosumab group showed a greater number of cases of breast cancer (35 vs 28 in PBO), cancer of the reproductive organs (21 vs 9 in PBO, mostly the ovaries), and of the GI tract (35 vs 24 in PBO). The latter was observed more specifically in the colon, pancreas, and stomach. With regard to the incidence of breast cancer in the two groups, there were only five more cases during year 3 in the group of nearly 4,000 women receiving denosumab than in those receiving PBO. It should also be noted that in the cancer trials (breast and other) involving thousands of patients treated monthly with double-dose (120 mg) denosumab for the prevention of skeletal-related events, overall disease progression and survival did not differ between denosumab and the comparator group (zoledronic acid) [93, 94].

Summary and perspective

RANKL, RANK, and OPG are not only expressed by bone cells but also by T cells, B cells, DCs, and monocyte–macrophages amongst others. Absence of RANKL or RANK during embryogenesis in mice results in thymus and LN defects, but this phenomenon has not been reported in humans with mutations in these genes. Hence, mutations in the TNFSF11 (RANKL) gene do not cause severe immune deficiencies nor have they been reported to result in an increased risk of infection, cancer, or immune disorders [8]. Nevertheless, mutations in the TNFRSF11A (RANK) gene may cause hypogammaglobulinemia in some patients, with a potentially increased risk of infection [9]. As underscored by Sobacchi et al. [8] "the contrast in the effects of mutations in the RANKL/RANK/OPG system between the knockout mouse phenotype and the human phenotype could be due to species-specific differences."

Blocking the RANKL/RANK pathway in adult rodents and monkeys apparently does not lead to major immune cell dysfunctions, in contrast to TNF-α or IL-1 inhibitors. As a corollary of its apparent lack of major effects on the immune system, RANKL inhibition does not prevent inflammation driven by T cells in RA or IBD. Inhibition by denosumab of RANKL binding to RANK has proven effective in preventing bone resorption and/or fractures and, to be generally safe, in patients with osteoporosis, RA, and non-metastatic (prostate and breast) cancer [16, 89, 91, 92]. Whether inhibition of T cell-mediated, RANKL-dependent

activation of DCs and monocyte–macrophages would affect the capacity to generate and/or control immune reactions (primarily to infection and cancer) in some tissues, like in the skin and colon, however, remains to be scrutinized as a large number of possibly older and thereby more immuno-compromised patients might be treated with denosumab in the future. On another side, RANK signaling also plays a role in the development of breast tissue [95], as well as in angiogenesis and endothelial permeability [96], which could be modified by RANKL inhibitors.

As denosumab progresses from investigation to clinical application, and as biological agents targeting cytokines are becoming more common in clinical practice, the efficacy and safety of association of biological agents, such as anti-TNF and denosumab for treatment of RA and other inflammatory diseases, will also need to be specifically investigated.

Conflicts of interest None.

References

1. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176
2. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602
3. Wada T, Nakashima T, Hiroshi N, Penninger JM (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25
4. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015–1024
5. Wada T, Nakashima T, Oliveira-dos-Santos AJ, Gasser J, Hara H, Schett G, Penninger JM (2005) The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med 11:394–399
6. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412–2424
7. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309
8. Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, Bredius R, Mancini G, Cant A, Bishop N, Grabowski P, Del Fattore A, Messina C, Errigo G, Coxon FP, Scott DI, Teti A, Rogers MJ, Vezzoni P, Villa A, Helfrich MH (2007) Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 39:960–962
9. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A (2008) Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSFiiA (RANK) mutations. Am J Hum Genet 83:64–76
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
11. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268
12. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540–3545
13. Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ (2009) One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 24:1234–1246
14. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831
15. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study G (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222–229
16. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309
17. Kearns AE, Khosla S, Kostenuik PJ (2008) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 29:155–192

18. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323

19. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP, Weitzmann MN (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839–3848

20. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T (1985) Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 135:2562–2568

21. Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA (2006) RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Bone 38:678–685

22. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, Kohashi O (1999) A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol 162:2754–2760

23. Butler DM, Malfait A-M, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM (1997) DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis. J Immunol 159:2867–2876

24. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605

25. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T et al (1990) IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297–3303

26. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R (2000) Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 96:1873–1878

27. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103:1345–1352

28. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516–518

29. Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005) Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208:228–251

30. Klaus J, Armbrecht G, Steinkamp M, Bruckel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C (2002) High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 51:654–658

31. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R (2003) Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 100:10405–10410

32. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179

33. Seshasayee D, Wang H, Lee WP, Gribling P, Ross J, Van Bruggen N, Carano R, Grewal IS (2004) A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 279:30202–30209

34. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563

35. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141–147

36. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761–1769

37. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997

38. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337:1029–1035

39. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126:989–996, discussion 947

40. Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44:1546–1548

41. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Aletaha D, Baker D, Han J, Bala M, St Clair EW (2009) Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann Rheum Dis 68:823–827

42. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939

43. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo- controlled, 52-week trial. Arthritis Rheum 50:1400–1411

44. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162–1167

45. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis

associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104

46. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155

47. Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291–302

48. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127

49. Olleros ML, Guler R, Vesin D, Parapanov R, Marchal G, Martinez-Soria E, Corazza N, Pache JC, Mueller C, Garcia I (2005) Contribution of transmembrane tumor necrosis factor to host defense against *Mycobacterium bovis bacillus* Calmette-Guerin and *Mycobacterium tuberculosis* infections. Am J Pathol 166:1109–1120

50. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168:4620–4627

51. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP (2003) Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 23:9824–9832

52. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E, Takahashi K, Furuya T, Ishiyama S, Kim KJ, Saito S, Nishikawa T, Takahashi N, Togari A, Tomatsu T, Suda T, Kamatani N (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003–1012

53. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269

54. Kim KW, Cho ML, Lee SH, Oh HJ, Kang CM, Ju JH, Min SY, Cho YG, Park SH, Kim HY (2007) Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett 110:54–64

55. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, Benoist C, Gravallese EM (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159:1689–1699

56. Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P (2009) RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-i therapies. Arthritis Res Ther 11:R187

57. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002) Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46:785–792

58. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442

59. Andrews NA (2008) Denosumab and the treatment of rheumatoid arthritis: in an occupied field, where will a RANKL inhibitor fit in? IBMS BoneKEy 5:351–556. http://www.bonekey-ibms.org/cgi/content/full/ibmske;5/i0/35i

60. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius

JK, Adamu S, Manoukian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G (2005) CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54:78–86

61. Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ, Carding SR (2003) Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19:849–861

62. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186:2075–2080

63. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y (2000) TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191:495–502

64. Mebius RE (2003) Organogenesis of lymphoid tissues. Nat Rev Immunol 3:292–303

65. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS (1996) Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J Exp Med 184:1999–2006

66. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA (1997) Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6:491–500

67. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K (1998) The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9:59–70

68. Kim D, Mebius RE, MacMicking JD, Jung S, Cupedo T, Castellanos Y, Rho J, Wong BR, Josien R, Kim N, Rennert PD, Choi Y (2000) Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 192:1467–1478

69. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353–362

70. Stolina M, Dwyer D, Ominsky MS, Corbin T, Van G, Bolon B, Sarosi I, McCabe J, Zack DJ, Kostenuik P (2007) Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 179:7497–7505

71. Maruyama K, Takada Y, Ray N, Kishimoto Y, Penninger JM, Yasuda H, Matsuo K (2006) Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice. J Immunol 177:3799–3805

72. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53:1–16

73. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW, Clark EA (2001) Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166:1482–1491

74. Kayagaki N, Yamaguchi N, Abe M, Hirose S, Shirai T, Okumura K, Yagita H (2002) Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL). Cell Immunol 219:82–91

75. Stolina M, Guo J, Faggioni R, Brown H, Senaldi G (2003) Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109:347–354

76. Stolina M, Ominsky MS, Schroeder J, Atkinson JE, Smith SY, LeSauteur L, Corneu S, Kostenuik PJ (2008) Long-term denosumab

treatment of non-human primates had no observed effects on leukocyte subsets or T-cell-dependent immune responses. Second International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems. 8–13 June 2008. Aegean Conference Series Vol. 35, p 98

77. Niederberger V, Niggemann B, Kraft D, Spitzauer S, Valenta R (2002) Evolution of IgM, IgE and IgG(1–4)antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur J Immunol 32:576–584

78. Diamant E, Melamed D (2004) Class switch recombination in B lymphopoiesis: a potential pathway for B cell autoimmunity. Autoimmun Rev 3:464–469

79. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252

80. Padigel UM, Kim N, Choi Y, Farrell JP (2003) TRANCE-RANK costimulation is required for IL-i2 production and the initiation of a Thi-type response to Leishmania major infection in CD40L-deficient mice. J Immunol 171:5437–5441

81. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y (1999) TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189:1025–1031

82. Josien R, Wong BR, Li HL, Steinman RM, Choi Y (1999) TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 162:2562–2568

83. Loser K, Mehling A, Loeser S, Apelt J, Kuhn A, Grabbe S, Schwarz T, Penninger JM, Beissert S (2006) Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 12:1372–1379

84. Barbaroux JB, Beleut M, Brisken C, Mueller CG, Groves RW (2008) Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation. J Immunol 181:1103–1108

85. Lambert C, Oury C, Dejardin E, Chariot A, Piette J, Malaise M, Merville MP, Franchimont N (2007) Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells. J Bone Miner Res 22:1350–1361

86. Holen I, Croucher PI, Hamdy FC, Eaton CL (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619–1623

87. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195

88. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119–129

89. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

90. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157

91. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755

92. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875–4882

93. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansay R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. Eur J Cancer Suppl 7:2

94. Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Jun S, Yeh H, Dansay R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Eur J Cancer Suppl 7:11

95. Fernandez-Valdivia R, Mukherjee A, Ying Y, Li J, Paquet M, DeMayo FJ, Lydon JP (2009) The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol 328:127–139

96. Min JK, Cho YL, Choi JH, Kim Y, Kim JH, Yu YS, Rho J, Mochizuki N, Kim YM, Oh GT, Kwon YG (2007) Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood 109:1495–1502

97. Miller RE, Branstetter D, Armstrong A, Kennedy B, Jones J, Cowan L, Bussiere J, Dougall WC (2007) Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179:266–274

98. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA (1996) Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 156:8–11

99. Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795–823